24小时热门版块排行榜

返回列表

【奖励】本帖被评价6次，作者xuanzixue增加金币 4.8 个

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

xuanzixue

铁虫 (正式写手)

应助: 7 (幼儿园)
金币: 4.3
帖子: 913
在线: 278.7小时
虫号: 961942

[资源] Avastin退出乳腺癌治疗，抗血管生成药物应该如何避免？

发自PNAS的文章：Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Antiangiogenic therapy has been thought to hold significant potential for the treatment of cancer. However, the efficacy of such treatments, especially in breast cancer patients, has been called into question, as recent clinical trials reveal only limited effectiveness of antiangiogenic agents in prolonging patient survival. New research using preclinical models further suggests that antiangiogenic agents
actually increase invasive and metastatic properties of breast cancer cells. We demonstrate that by generating intratumoral hypoxia in human breast cancer xenografts, the antiangiogenic agents sunitinib andbevacizumab increase the population of cancer stemcells. In vitro studies revealed that hypoxia-driven stem/progenitor cell enrichment is primarily mediated by hypoxia-inducible factor 1α. We further show that the Akt/β-catenin cancer stem cell regulatory pathway
is activated in breast cancer cells under hypoxic conditions in vitro and in sunitinib-treated mouse xenografts. These studies demonstrate that hypoxia-driven cancer stem cell stimulation limits the effectiveness of antiangiogenic agents, and suggest that to improve patient outcome, these agents might have to be combined
with cancer stem cell-targeting drugs.

回复此楼

» 本帖附件资源列表

欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com
附件 1 : AntiangiogenicagentsincreasebreastcancerPMIDb22308314.pdf

2013-03-14 18:25:45, 1.47 M